Are drugs within a class interchangeable?

Lancet

Volumn 354, Issue 9185, 1999, Pages 1202-1204

  Furberg, Curt D ^a   Herrington, David M ^a   Psaty, Bruce M ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; MIBEFRADIL; NONSTEROID ANTIINFLAMMATORY AGENT; PRACTOLOL; PRAVASTATIN; PRONETALOL; SIMVASTATIN;

CARDIOVASCULAR DISEASE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; THROMBOSIS;

EID: 0033517525     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03190-6     Document Type: Note

References (14)

1. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
2. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. JAMA. 279:1998;1643-1650.
3. Furberg C.D. Natural statins and stroke risk. Circulation. 99:1999;185-188.
4. Pitt B. Use of 'Xapril' in patients with chronic heart failure: a paradigm or epitaph for our times? Circulation. 90:1994;1550-1551.
5. Cushman D.W., Wang F.L., Fung W.C.et al. Comparisons in vitro, ex vivo, and in vivo of actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol. 28:1989;115-131.
6. Yusuf S., Peto R., Lewis J.et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.
7. Soriano J.B., Hoes A.W., Meems L., Grobbee D.E. Increased survival with β-blockers: importance of ancillary properties. Prog Cardiovasc Dis. 39:1997;445-456.
8. Packer M. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. Eur Heart J. 19:1998;40-46.
9. Department of Health and Human Services. Single-Entity Barbiturates; class labeling guidance. Federal Register. 45:1980;76356-76367.
10. Division of Drug Marketing, Advertising and Communications. Food and Drug Administration, Department of Health and Human Services. Rockville: FDA Warning Letter to Novartis Pharmaceuticals Corporation, 1999.
11. Venning G.R. Identification of adverse reactions to new drugs. II: How were 18 important adverse reactions discovered and with what delays? BMJ. 286:1983;289-292.
12. Wolfe SM. Differences in the number of drug safety withdrawals. United States. United Kingdom, Germany, France 1970-1992. Washington DC: Public Citizen's Health Research Group, 1995.
13. Roche Laboratories announces withdrawal of Posicor from the market. US Food and Drug Administration. Rockville: US Department of Health and Human Services, Public Health Service, 1998.
14. Thomas M., Mann J. Increased thrombotic vascular events after change of statin. Lancet. 352:1998;1830-1831.